Skip to content
ML2

Source: Google DeepMind: AlphaGenome 2

Google DeepMind releases AlphaGenome 2 on its research API

Why it matters

Google DeepMind has released AlphaGenome 2, a DNA sequence model that predicts how genetic variants change gene activity in specific human cell types rather than across broad tissue averages. It is available today through the AlphaGenome API, free for non-commercial research, with commercial research access in private preview only.

Unlike the first model, which predicted thousands of tissue tracks in parallel, AlphaGenome 2 is conditional: you pass a million-letter DNA sequence plus one target condition (a tissue, cell type or state, picked from a reference catalogue or built on the fly from your own single-cell data), and it adds DNA methylation to the readouts it predicts.

DeepMind says it was trained on more than 107 million single-cell profiles from human and mouse samples and can condition on a new single-cell RNA-seq snapshot from a few dozen cells without retraining. The performance figures are DeepMind's own: on the TenK10K immune-cell dataset it says AlphaGenome 2 identified 30% of causal variants versus 16% for a fine-tuned AlphaGenome 1, and 43% versus 23% of directional gene effects.

In the Python client it lives at alphagenome.models.v2; the docs say to use it for new analyses and keep AlphaGenome 1 to reproduce the original paper or score all tissues at once, note that AlphaGenome 2 returns raw scores only, with no quantile calibration, and list four input widths from 16 KB to 1 MB, with 1 MB recommended.

The terms matter: API outputs are for non-commercial research only, must not be used to train other models and must not be used for clinical decisions; commercial work goes through Google Cloud Model Garden. DeepMind says AlphaGenome 2 Skills for Google Antigravity are coming soon but has not given a date.

If you build bioinformatics pipelines or research agents, get a free API key and try the v2 client on a small set of variants; it is not a general-purpose model and not something to put behind a commercial product yet.

Sources

All notes on This week →

Newsletter

Get the best new A.I. picks in your inbox

The best new agent workflows and tools we’ve vetted, with a clear verdict on each. Short, occasional, useful.

Free. No spam. Unsubscribe anytime.